EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

Benjamin J Murdock iD, Jihyun Park, Dae-Gyu Jang iD, Bangyao Zhao, Samuel J Teener, Ian F Webber-Davis, Lili Zhao, Eva L Feldman iD, Stephen A Goutman iD

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Benjamin J Murdock und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Killer Cells, Natural, Piperidines, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Peter R. Clark Fund for ALS Research, Coleman Discovery Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell profiles can predict responsiveness to tofacitinib, and assess the role of NK cell cytotoxicity in ALS progression.

Methods

Primary NK cells were isolated from peripheral blood samples of ALS participants and healthy controls. NK cells were then co‐cultured with target cancer cells, with or without tofacitinib, to assess their cytotoxic activity. Flow cytometry was used to generate immune profiles for each participant, based on 154 immune markers, to explore correlations with NK cell cytotoxicity and response to tofacitinib. The potential association between NK cell cytotoxicity and disease severity, as measured by the revised ALS Functional Rating Scale, was also assessed. All analyses were stratified by age and sex.

Results

Tofacitinib effectively reduced the cytotoxicity of primary NK cells isolated from the blood of ALS participants ( n = 80) and healthy controls ( n = 71), with immune cell profiles correlating with the response to tofacitinib. However, NK cell cytotoxicity was lower in ALS participants compared to healthy controls and showed no association with ALS progression.

Interpretation

These findings confirm that tofacitinib suppresses NK cell cytotoxicity, and that immune profiling may help identify treatment responder groups. However, further research is needed to fully understand the role and timing of NK cell activity in ALS pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisKiller Cells, NaturalPiperidinesPyrimidinesCytotoxicity, ImmunologicProtein Kinase InhibitorsHumansFemaleMaleMiddle AgedAgedPrecision MedicineAdult

Stichwörter der Autor:innen

amyotrophic lateral sclerosiscytotoxicityimmune profilesnatural killer cellstofacitinib

Substanzen

PiperidinesPyrimidinestofacitinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Benjamin J Murdock, Dae-Gyu Jang, Eva L Feldman, Stephen A Goutman

Förderung

  • NIH HHS
  • Peter R. Clark Fund for ALS Research
  • Coleman Discovery Fund
  • ALS Association
  • Scott L. Pranger
  • ACL HHS
  • ATSDR CDC HHS
  • NINDS NIH HHS

Zitieren

APA

Murdock, B. J., Park, J., Jang, D. G., Zhao, B., Teener, S. J., Webber-Davis, I. F., Zhao, L., Feldman, E. L., & Goutman, S. A. (2025). In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70127

Vancouver

Murdock BJ, Park J, Jang DG, Zhao B, Teener SJ, Webber-Davis IF, et al. In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70127

BibTeX
@article{Murdock2025,
  author = {Murdock, Benjamin J and Park, Jihyun and Jang, Dae-Gyu and Zhao, Bangyao and Teener, Samuel J and Webber-Davis, Ian F and Zhao, Lili and Feldman, Eva L and Goutman, Stephen A},
  title = {In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70127}
}
Kostenlos starten →